Progressive Supranuclear Palsy (PSP) is a movement disorder with prominent tau neuropathology. A genome wide association study of PSP was performed to identify genes that modify risk for this primary tauopothy; GWAS data available in NG00037. A two-stage analysis was performed to maximize efficiency while maintaining power. Stage 1 is comprised of autopsied cases and stage 2 contains clinically diagnosed PSP cases.
Available in this dataset are the summary statistics described in Hoglinger et al. The p-value data is generally available to all users using the link below; however, gaining access to the allele frequencies requires a formal data request.
Download P-value only data here.
Search SNPs passing specific p-value cut-off, and view functional impacts and other annotations in the NIAGADS Genomics DB.
The NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) is supported by a collaborative agreement from the National Institute on Aging, U24AG041689.
NG00045: This work was funded by grants from the CurePSP Foundation, the Peebler PSP Research Foundation, and National Institutes on Health (NIH) grants R37 AG 11762, R01 PAS-03-092, P50 NS72187, P01 AG17216 [National Institute on Aging(NIA)/NIH], MH057881 and MH077930 [National Institute of Mental Health (NIMH)]. Work was also supported in part by the NIA Intramural Research Program, the German National Genome Research Network (01GS08136-4) and the Deutsche Forschungsgemeinschaft (HO 2402/6-1), Prinses Beatrix Fonds (JCvS, 01–0128), the Reta Lila Weston Trust and the UK Medical Research Council (RdS: G0501560). The Newcastle Brain Tissue Resource provided tissue and is funded in part by a grant from the UK Medical Research Council (G0400074), by the Newcastle NIHR Biomedical Research Centre in Ageing and Age Related Diseases to the Newcastle upon Tyne Hospitals NHS Foundation Trust, and by a grant from the Alzheimer’s Society and Alzheimer’s Research Trust as part of the Brains for Dementia Resarch Project. We acknowledge the contribution of many tissue samples from the Harvard Brain Tissue Resource Center. We also acknowledge the 'Human Genetic Bank of Patients affected by Parkinson Disease and parkinsonism' (http://www.parkinson.it/dnabank.html) of the Telethon Genetic Biobank Network, supported by TELETHON Italy (project n. GTB07001) and by Fondazione Grigioni per il Morbo di Parkinson. The University of Toronto sample collection was supported by grants from Wellcome Trust, Howard Hughes Medical Institute, and the Canadian Institute of Health Research. Brain-Net-Germany is supported by BMBF (01GI0505). RdS, AJL and JAH are funded by the Reta Lila Weston Trust and the PSP (Europe) Association. RdS is funded by the UK Medical Research Council (Grant G0501560) and Cure PSP+. ZKW is partially supported by the NIH/NINDS 1RC2NS070276, NS057567, P50NS072187, Mayo Clinic Florida (MCF)Research Committee CR programs (MCF #90052030 and MCF #90052030), and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch (MCF #90052031/PAU #90052). The Mayo Clinic College of Medicine would like to acknowledge Matt Baker, Richard Crook, Mariely DeJesus-Hernandez and Nicola Rutherford for their preparation of samples. PP was supported by a grant from the Government of Navarra ("Ayudas para la Realización de Proyectos de Investigación" 2006–2007)
GWAS summary statistics data from controls were obtained from the Center for Applied Genomics at The Children's Hospital of Philadelphia (PI: Hakon Hakonarson, MD, PhD). If the control summary statistics data is being used for other studies, please acknowledge as follows: We thank the Center for Applied Genomics (PI: Hakon Hakonarson, MD, PhD) at The Children's Hospital of Philadelphia for providing access to GWAS summary statistics data from controls.